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Summary.-Sera were collected from patients with acute myelogenous leukaemia
(AML) at various times during remission induced by chemotherapy, but after
cessation of all immunosuppressive treatment. These sera were tested, by a sensitive
assay using radio-labelled antiglobulin binding, for the presence of antibodies
which bound to the surface of autologous AML cells. The cell populations examined
were chosen on the basis that they proliferated in short-term culture, did not bind
anti-Ig reagents directly, and that more than80% ofthe cells did not carry detectable
Fc receptors. With8/9 patients studied, no specific antibodies ofthe IgG or IgM class
could be detected in serum samples taken during remission. IgG and IgM antibodies
from the remission sera of one patient were found to bind to autologous leukaemic
cells, but this was found to be due to the presence of rheumatoid factor (RF) and
removal of the RF activity abolished this binding.
This study has, like others, failed to detectautologousantibodies,inremission sera,
that are directed against membrane components of AML cells.
EVIDENCE FOR AN ANTIGEN associated
with human acute myelogenous leukaemia
(AML) has been adduced from the finding
that lymphocytes taken from patients in
remission are stimulated into DNA syn-
thesis in co-culture with autologous leuk-
aemic cells (Fridman & Kourilsky, 1969;
Anderson et al., 1974; Cocks et al., 1977).
The interpretation of the data obtained
in these experiments, however, has been
complicated by the discovery that under
some conditions B cells from normal
healthy individuals can stimulate their
autologous T cells (Opelz et al., 1975;
Bergholtz et at., 1977) and by the failure
to find, in patients during remission,
lymphocytes that are cytotoxic for autolo-
gous leukaemic cells (Hopkins & Alex-
ander, unpublished). Moreover, attempts
to detect, during remission, serum anti-
bodies that are cytotoxic to autologous
AML cells, either with complement or in a
cell-dependent-antibody assay, have been
unsuccessful (Gale & MacLennan, 1977;
Chapuis et al., 1978).
The present investigation set out to
determine whether non-lytic autologous
antibodies could be detected in remission
sera, by a sensitive assay using radio-
labelled-antiglobulin binding, which we
findtobemoresensitive than complement-
dependent cytotoxicity for the detection
ofalloantibodies (anti-HLA) on AML cells.
The target cells used in this assay must
be free of surface-associated immuno-
globulin (Ig) which may be carried over
when the cells are collected from the
patient, and for this reason we used only
AML cells that have been cultured in
vitro for 4-6 days. Not all the populations
of AML cells which grew in vitro were
suitable for this assay. Some had to be
excluded because of the presence of Fc
receptor-bearing cells which might have
complicated the binding assay; others
were not used because they bound theS. E. JAMES, C. J. DEAN AND P. ALEXANDER
anti-Ig reagents directly (i.e. without
their previous exposure to human serum).
Of 32 populations of AML cells which had
been collected at presentation and stored
in liquid N2 (Chapuis et al., 1977) and for
which remission sera were available, 9
fulfilled the above criteria.
MATERIALS AND METHODS
Leukaemic cells.-AML cells cryopreserved
by the method of Chapuis et al. (1977) were
thawed rapidly at 37°C, diluted slowly with
RPM1 1640 medium, spun down at 400 g for
5 min, washed twice with the medium, and
finally resuspended at a concentration of
3 x 106/ml in medium supplemented with 15%
foetal calf serum (FCS), 100 u/ml penicillin,
100 u/ml streptomycin and 300 jug/ml
L-glutamine. Aliquots of 3 ml were plated
into 35mm-diameter multi-well plates (No.
313 Sterilin Ltd, Richmond, Surrey). After
at least 4 days in culture at 37°C, viable cells
were harvested by centrifugation on 10 ml of
"Lymphoprep" gradient (Nyegaard and Co.,
Oslo). Interface cells were collected, washed
twice and resuspended in medium plus 10%
FCS (at a concentration of 2 x 107 cells/ml).
Determination ofFc receptors-.The method
used was that described by Palu et al. (1979).
Controls using unsensitized SRBC were in-
cluded. Only populations containing <20%
Fc receptor-bearing cells were used in this
investigation.
Serum.-Serum samples taken from
patients at presentation, and during re-
mission, were stored as 5ml aliquots at
-20°C. Before use, each sample was thawed
and centrifuged for 30 min at 20,000 rev/min
in a Beckman S.W.50.1 Rotor to separate off
lipid and other insoluble materials. Sodium
azide was added to a concentration of0-020/
and the samples were stored at 4°C during
use. Normal serum ofthe AB blood group was
obtained from the S.W. Regional Blood
Bank, and a polyspecific anti-HLA serum was
provided by Dr Sylvia Lawler.
Preparation of 1251-labelled affinity-purified
anti-human IgG and IgM.-Human IgG and
IgM were prepared by standard procedures
from either pooled normal serum or myeloma
serum (Fahey & Terry, 1979) and then
coupled to CNBr-activated Sepharose-4B
(Pharmacia Fine Chemicals, Uppsala,
Sweden).
Sheep antibodies to human IgG and rabbit
antibodies to human IgM, which had been
absorbed first to remove unwanted speci-
ficities, were then adsorbed to the respective
affinity column. After washing with phos-
phate-buffered saline (PBS), pH 7-4, con-
taining lM NaCl, the specific antibodies were
eluted with 3M KSCN and dialysed exten-
sively against PBS containing 0.02% NaN3.
The affinity-purified antibodies were
labelled with 125lodine according to the
method of McConahey & Dixon (1966) to a
specific activity of 1-5 ,tCi/tg of protein.
Absorption ofAML sera with cultured AML
cells.-200,1t aliquots of AML sera (diluted
1: 2 with medium) were incubated with
2 x 107 autologous or allogeneic cultured
AML cells for 16 h at 4°C. The cells were
centrifuged down and the absorbed serum
removed.
Rheumatoid Factor (RF).-Serum samples
were tested for RF by latex agglutination
(Latex-RF Reagent, Hoechst Pharma-
ceuticals, Hounslow, Middlesex).
(a) Absorption of RF from AML sera on
aggregated human IgG: human IgG, aggre-
gated by heating at 63TC for 30 min, was
linked to CNBr-activated Sepharose-4B to
give a final concentration of about 5 mg
protein/ml of gel.
A 200,iu packed volume of Sepharose-
aggregated IgG was mixed with an equal
volume of AML serum diluted 1:2 with
medium+ 10% FCS and rotated overnight at
4°C. After centrifugation the absorbed serum
was removed and retested for RF by latex
agglutination, and for binding to autologous
cultured AML cells.
(b) Purification of RF: 30 ml of plasma
obtained from a patient with rheumatoid
arthritis (RF titre 1:320) was diluted 1:5
with PBS-azide and decomplemented by
heating at 56°C for 30 min. The RF was
adsorbed to a column of Sepharose-aggre-
gated human IgG, then after washing with
PBS containing IM NaCl, the RF was eluted
with 3M KSCN and dialysed against PBS-
azide. The RF obtained (5-7 mg protein in
15 ml) had an agglutination titre of 1:80.
Whilst the principal protein in this prepara-
tion was IgM, some IgG (< 10% of total
protein) could be detected by double-diffusion
analysis (Ouchterlony, 1948).
Radiolabelled-antiglobulin-binding assay.-
50ul doubling dilutions of serum (usually
starting at 1: 2, and made in medium con-
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taining 10% FCS) were prepared in Micro-
titer plates (Sterilin Ltd, Richmond, Surrey)
and 50 ,ul of cultured AML cell suspension
were added to give a final concentration of
106 cells per well. After incubation at 37°C
for 30 min, the plates were centrifuged at
1000 rev/min for 2 min in an MSE Multex'
centrifuge and the cell pellets waashed x 4
and finally resuspended in 100 ,u of either
1251-anti-IgG or 1251-anti-lgM (diluted to
give 2 x 105 ct/min/well). After incubation on
ice for 30 min the cells were washed x 3 and
resuspended in 100 ,ul medium, and the con-
tents of each -well transferred to a, disposable
plastic tube (LP3, Luckhams Ltd, Burgess
Hill, Sussex) and counted in a Packard Auto-
gamma Spectrometer.
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1: 4 dilution of the purified RF. incubated on
ice for 30 min and washed twice before
treatment with the 1251-labelled antiglobulin
reagent.
RESULTS
Sera from 9 AMIL patients, taken at
various times during remission, were ex-
amined for the presence of antibodies
binding to the plasma membrane of cul-
tured autologous leukaemic cells. The
negative control was normal AB serum
(NHS) and the positive control poly-
specific anti-HLA sertum.
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FIGURE. The binding of 125I aniti-IgG an(d 125I ant,i-IgMI by cultured AMIL cells of Patient C.L. The
cells were either untreated ( ) or exposed to normal serum (D), anti-HLA serum ( ) or autologous
serum collected during remission (0 -*). The results shown here were obtained with a 1:8
sertum dilution. The RF titres ofthe individual sera are also shown. The patient relapse(d at WVeek 55.
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After exposure to autologous sera, 8 of
the 9 cell populations showednobinding of
anti-IgG or anti-IgM above that seen with
the NHS. Significant binding ofautologous
antibodies was found only with cells from
Patient C.L. (Table I) in whom the
apparent levels of IgG antibody rose
during the first 5 months in remission and
then fell. High levels of IgM were also
found in remission sera, and these levels
fell only when the patient relapsed
(Figure).
Three of the high-binding sera from
Patient C.L. were pooled (Pool A) as were
3 of the low-binding sera (Pool B) and
examined for specificity by absorption on
the patient's own cultured AML cells, and
for cross-reactivity by absorption on 4
allogeneic cultured AML cell populations
(Table II). Absorption of the pooled sera
TABLE II.-The effect 6fabsorption of C.L.
sera with AML cells on the subsequent
binding of IgM to autologous cells
1251 anti-IgM ct/min bound by
C.L. cells after exposure to
Norma
that for each sample there was a correla-
tion between the level of cell-bound IgM
and the titre of RF; i.e. both were high
during remission and fell as the patient
relapsed.
TABLE III.-The effect on antibody binding
and rheumatoid factor (RF) titre of C.L.
seraafterabsorptionwithautologous AML
cells or aggregated human IgG
Treatment of C.L.
serum
No serum
Pool A
None
Absorption on
aggregated IgG
Absorption on 2 x 107
autologous cells
Pool B
None
Absorption on
aggregated IgG
Absorption on 2 x 107
autologous cells
* 1:8 dilution of serum.
125I antiglobulin
bound by C.L.
cells (ct/min)
anti- anti-
IgG* IgM*
1,750 1,945
RF
titre
5,516 22,154 1:320
2,516 12,249 1:20
3,349 7,653 + 1: 20
3,054 15,944 1:40
2,712 7,700 <1:20
2,631 8,660 < 1:20
Treatment
of sera*
None
Absorption on
cells from
patients:
R.D.
V.T.
H.N.
S.M.
C.L.
C.L.
pool At
23,306
17,034
21,226
24,683
16,767
17,313
C.L.
pool Bt
15,571
9,938
12,080
15,975
11,114
8-606
Normal
serumt
9,753
No
serum
996
4,353
5,587
9,476
5,477
3,803
* 200 p1 of a 1:2 dilution of C.L. sera, Pool A and
Pool B, or AB normal serum, were absorbed once
with 2 x 107 cultured AML cells.
t 1: 8 dilution of serum.
on C.L. cells and 3/4 allogeneic cell popu-
lations reduced the subsequent binding of
immunoglobulin to cells of Patient C.L.
These results indicate that the Igs present
in C.L.'s sera were not specific for C.L.'s
cells.
The patients' sera were tested for RF
and all those collected from the first 8
patients were negative by latex agglutina-
tion. All sera from Patients C.L., however,
were positive for RF and the Figure shows
28
Absorption of C.L. sera with Sepharose-
linked aggregated human IgG reduced
both the titre ofRF and the amount of Ig
bound by the cultured cells (Table III).
This indicates that some or all ofthe anti-
IgG and anti-IgM binding was due to the
presence of RF in the sera. To distinguish
between the possibilities (a) that the RF
bound to IgG antibodies that had com-
plexed with cell-surface antigens and so
"amplified" the binding of autologous
antibody, or (b) that the cultured AML
cells possessed receptors for RF; the bind-
ing of purified RF to 3 different popula-
tions of cultured AML cells was deter-
mined (Table IV). When these cells were
treated with the anti-HLA serum before
exposure to RF, the quantity of 1251 anti-
IgM bound subsequently was greater than
in cells treated with just RF. Only a small
effect was seen when the normal AB
serum had been used. All 3 cell popula-
tions were then examined for RF binding
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TABLE IV. The effect of treatment with rheurnatoid factor on the binding of 1251-labelled
antiglobulin to cultured AML cells sensitized with human sera
ct/min 1'251-antiglobulin boundl by AML cells of Patients
SeruLm use( fol
sensitization
(I : 8 (lilution)
Anti-IgG
None
AB NHS
Anti-HLA
Autologous
Mean
Highest value
Anti-IgMl
None
AB NHS
Anti-HLA
Autologouis
Mean
Highest xalue
R.C.
-RF +RF
1,279 1,558
1,037 1,365
4,809 4,979
1,138 1,457
1,34:3 1,854
914 6,478
2,422 6,715
2,12:3 18,720
1,925 6,394
3,196 6,847
S8.M.
A.
-RF +RF
1,756 3,667
3,469 5,693
16,048 15,397
3,767 4,895
4,664 6,055
1,51:3 13,177
3,046 11,950
2,998 25,211
2,791 11,399
3,181 13,576
C.L.
-RF +RF
1,581 4,119
3,492 6,305
7,480 12,453
3,025 4,947
5,74:3 7,101
644
5,478
2,587
19,039
23,799
31,171
12,875 22,595
18,134 225,581
(determined with 1251 anti-IgM) following
their exposure to autologous serum. In no
case was there an increase in the quantitv
of 1251 anti-IgM bound over that given by
the cells pretreated with normal AB
serum.
DISCUSSION
This investigation, like those using
cytotoxicity as an end-point, has failed to
reveal specific antibodies of the IgG or
IgM classes in sera taken from patients at
various times during remission and tested
in an antibody-binding assay on autolo-
gous leukaemic cells. We have excluded
false positives due to the presence of Fc
receptors or Ig carried over when the cells
were collected from the patients at pre-
sentation, by culturing the cells before
screening them for the binding of either
antibody-coated sheep red blood cells or
1251 anti-Ig. Cell populations that were
positive (i.e. > 20% positive cells) were
excluded from further tests.
To establish that antibodies against
surface antigens could be detected, each
population of cultured AML cells was ex-
posed to a polyvalent human anti-HLA
serum. The radioassays showed that, with
8/9 AML patients, none of the sera taken
during remission contained antibodies
which bound to their autologous leuk-
aemic cells. However, sera from one
patient (C.L.)-notably those taken early
in remission apparently contained both
IgG and IgM antibodies which bound to
the patient's own cultured AML cells, but
the Igs involved were cross-reactive be-
cause they could be absorbed out by AML
cells from some other patients. The bound
Igs were shown not to be directed against
a common leukaemia antigen, but the
binding was due to rheumatoid factor
present only in the remission sera of
Patient C.L. We conclude from the
adsorption tests that some, but not all,
cultured AML populations have "recep-
tors" for RF (either alone or complexed)
or IgM.
The binding of 1251 anti-IgM to anti-
HLA-coated AML cells was enhanced by
exposure of the sensitized cells to RF
before application of the 1251 antiglobulin.
No evidence was obtained to show, how-
ever, that an intermediate treatment with
RF would reveal membrane-bound autolo-
gous antibodies that were previously un-
detectable.
Recently, Henle et al. (1979) have re-
ported that the presence of RF in the sera,
of patients with rheumatoid arthritis or
with a variety of neoplastic diseases gave
rise to misleading answers in tests for
antibodies to Epstein-Barr virus. Giuliano
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et al. (1979) have also shown that RF in
the sera from melanoma patients inter-
feres with tests for cell-bound antibody.
The patients examined in the present
study were treated initially with intensive
chemotherapy, until they became clinic-
ally disease-free. While in remission they
received no immunosuppressive therapy,
and the only treatment was inoculation
with BCG and irradiated allogeneic leuk-
aemic cells (Powles, 1973). It has been
shown that during this time the patients'
lymphocytes react normally in the mixed-
lymphocyte reaction (Cocks et al., 1977)
and cytotoxic alloantibodies could be
detected in remission sera after challenge
with allogeneic leukaemic cells (Chapuis
et al., 1978). Accordingly, the failure to
detect antibodies to autologous leukaemic
cells cannot be attributed to immuno-
suppressive treatment.
We are grateful to Dr R. Powles for his help and
advice and for making available to us sera and
leukaemic cells from his AML patients.
This work was supported by a programme grant
from the Medical Research Council.
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